Payment overview · 2025
General Payments
$348.72
14 reported records · 6 companies
Healthcare provider profile · identity verified
Barry S Meyer, DO
Allopathic & Osteopathic Physicians|Internal Medicine · WARREN, MI · NPI 1194706580
Verified facts
What the public records show
CMS Open Payments records show Barry S Meyer, DO received $348.72 in general payments during 2025 across 14 reported records.
AstraZeneca Pharmaceuticals LP accounted for 57.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 363 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $199.33 | 57.2% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $50.76 | 14.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.63 | 12.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.12 | 5.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.67 | 5.3% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $15.21 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $348.72 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $120.91 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $50.76 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
79 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
363 | 49 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1100 | 110 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 577 | 114 |
| Ozempic | Semaglutide | 363 | 49 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 305 | 42 |
| Simvastatin | Simvastatin | 279 | 74 |
| Lisinopril | Lisinopril | 252 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 248 | 57 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 236 | 58 |
| Losartan Potassium | Losartan Potassium | 234 | 63 |
| Atorvastatin Calcium | Atorvastatin Calcium | 224 | 59 |
| Metformin Hcl | Metformin Hcl | 224 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 221 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 208 | 55 |
| Ibuprofen | Ibuprofen | 187 | 37 |
| Mometasone Furoate | Mometasone Furoate | 183 | 18 |
| Omeprazole | Omeprazole | 176 | 60 |
| Furosemide | Furosemide | 170 | 46 |
| Prednisone | Prednisone | 166 | 81 |
| Azithromycin | Azithromycin | 161 | 100 |
| Metoprolol Tartrate | Metoprolol Tartrate | 161 | 41 |
| Naproxen | Naproxen | 153 | 50 |
| Sertraline Hcl | Sertraline Hcl | 143 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 125 | 28 |
| Gabapentin | Gabapentin | 124 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 122 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 29 |
| Alprazolam | Alprazolam | 108 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 108 | 28 |
| Celecoxib | Celecoxib | 103 | 26 |
| Ketoconazole | Ketoconazole | 103 | 20 |
| Levofloxacin | Levofloxacin | 99 | 51 |
| Spironolactone | Spironolactone | 95 | 28 |
| Tramadol Hcl | Tramadol Hcl | 87 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 86 | 11 |
| Promethazine Hcl | Promethazine Hcl | 85 | 43 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 16 |
| Linzess | Linaclotide | 80 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 15 |
| Varenicline Tartrate | Varenicline Tartrate | 79 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 29 |
| Eliquis | Apixaban | 75 | 20 |
| Lubiprostone | Lubiprostone | 72 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 72 | 23 |
| Mupirocin | Mupirocin | 68 | 39 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 66 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 65 | 19 |
| Dexlansoprazole Dr | Dexlansoprazole | 65 | 19 |
| Alendronate Sodium | Alendronate Sodium | 62 | 15 |
| Famotidine | Famotidine | 55 | 25 |
| Januvia | Sitagliptin Phosphate | 53 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 51 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 51 | 20 |
| Montelukast Sodium | Montelukast Sodium | 50 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 47 | 19 |
| Fluconazole | Fluconazole | 45 | 26 |
| Carvedilol | Carvedilol | 44 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 11 |
| Meclizine Hcl | Meclizine Hcl | 42 | 18 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 40 | 14 |
| Glipizide | Glipizide | 40 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 40 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 40 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | suppressed |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Allopurinol | Allopurinol | 37 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | 11 |
| Arnuity Ellipta | Fluticasone Furoate | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 32 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | 13 |
| Hydrocortisone | Hydrocortisone | 30 | 19 |
| Meloxicam | Meloxicam | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 28 | suppressed |
| Epinephrine | Epinephrine | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 11 |
| Finasteride | Finasteride | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Potassium Chloride | Potassium Chloride | 25 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 24 | suppressed |
| Procto-Med Hc | Hydrocortisone | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Verapamil Sr | Verapamil Hcl | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 20 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 14 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 17 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 14 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Naproxen Sodium Cr | Naproxen Sodium | 13 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Copaxone | Glatiramer Acetate | 11 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $348.72 · 14 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, OTEZLA, Ohtuvayre, REPATHA, TRELEGY ELLIPTA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error